Qurient Co. Ltd (115180) - Total Liabilities

Latest as of June 2026: ₩23.76 Billion KRW ≈ $16.10 Million USD

Based on the latest financial reports, Qurient Co. Ltd (115180) has total liabilities worth ₩23.76 Billion KRW (≈ $16.10 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Qurient Co. Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Qurient Co. Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Qurient Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Qurient Co. Ltd total assets.

Qurient Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Qurient Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Jamna Auto Industries Limited
NSE:JAMNAAUTO
India Rs4.28 Billion
Atos SE
PA:ATO
France €7.27 Billion
First Sensor AG
F:SIS
Germany €39.54 Million
Churchill Capital Corp XI
NASDAQ:CCXI
USA $154.36 Million
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
China CN¥1.64 Billion
Queen's Road Capital Investment Ltd.
TO:QRC
Canada CA$37.50 Million
S&S TECH Corporation
KQ:101490
Korea ₩83.66 Billion
Beijing Sanlian Hope Shin-Gosen Technical Service Co Ltd
SHE:300384
China CN¥541.65 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Qurient Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 115180 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 10.35 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.52 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Qurient Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Qurient Co. Ltd (2014–2025)

The table below shows the annual total liabilities of Qurient Co. Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩22.80 Billion
≈ $15.45 Million
+185.93%
2024-12-31 ₩7.97 Billion
≈ $5.40 Million
+35.53%
2023-12-31 ₩5.88 Billion
≈ $3.99 Million
+79.65%
2022-12-31 ₩3.28 Billion
≈ $2.22 Million
-7.61%
2021-12-31 ₩3.55 Billion
≈ $2.40 Million
-16.46%
2020-12-31 ₩4.24 Billion
≈ $2.88 Million
+35.36%
2019-12-31 ₩3.14 Billion
≈ $2.12 Million
-17.30%
2018-12-31 ₩3.79 Billion
≈ $2.57 Million
+230.89%
2017-12-31 ₩1.15 Billion
≈ $776.40K
-39.40%
2016-12-31 ₩1.89 Billion
≈ $1.28 Million
+96.17%
2015-12-31 ₩963.76 Million
≈ $653.12K
-97.09%
2014-12-31 ₩33.11 Billion
≈ $22.44 Million
--

About Qurient Co. Ltd

KQ:115180 Korea Biotechnology
Market Cap
$540.41 Million
₩797.43 Billion KRW
Market Cap Rank
#11947 Global
#324 in Korea
Share Price
₩21400.00
Change (1 day)
-4.46%
52-Week Range
₩14320.00 - ₩50900.00
All Time High
₩50900.00
About

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company's pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as … Read more